P
Peng Zhao
Researcher at Chinese PLA General Hospital
Publications - 16
Citations - 8249
Peng Zhao is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: CD8 & Adverse effect. The author has an hindex of 11, co-authored 16 publications receiving 6018 citations.
Papers
More filters
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score.
Dong Ji,Dawei Zhang,Jing Xu,Zhu Chen,Tieniu Yang,Peng Zhao,Guofeng Chen,Gregory Cheng,Yudong Wang,Jingfeng Bi,Lin Tan,George Lau,Enqiang Qin +12 more
TL;DR: Using the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources.
Journal ArticleDOI
Immunological and inflammatory profiles in mild and severe cases of COVID-19.
Jin-Wen Song,Chao Zhang,Xing Fan,Fan Ping Meng,Zhe Xu,Peng Xia,Wen-Jing Cao,Wen-Jing Cao,Tao Yang,Xiao Peng Dai,Si Yu Wang,Ruo Nan Xu,Tian Jun Jiang,Wen Gang Li,Dawei Zhang,Peng Zhao,Ming Shi,Chiara Agrati,Giuseppe Ippolito,Markus Maeurer,Alimuddin Zumla,Fu-Sheng Wang,Ji Yuan Zhang +22 more
TL;DR: A higher degree of lymphopenia in various immune cell subsets as well as cytotoxicity and T cell inhibitory marker expression in severe cases compared with mild, indicate that immune-based targets for therapeutic interventions constitute a promising treatment for severe COVID-19 patients.
Journal ArticleDOI
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Fanping Meng,Ruonan Xu,Siyu Wang,Zhe Xu,Chao Zhang,Yuanyuan Li,Tao Yang,Lei Shi,Junliang Fu,Tian-Jun Jiang,Lei Huang,Peng Zhao,Xin Yuan,Xing Fan,Ji-Yuan Zhang,Jin-Wen Song,Dawei Zhang,Yan-Mei Jiao,Limin Liu,Chun-Bao Zhou,Markus Maeurer,Alimuddin Zumla,Alimuddin Zumla,Ming Shi,Fu-Sheng Wang +24 more
TL;DR: Evaluated data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated, and phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC- MSCs to reduce deaths and improve long- term treatment outcomes.
Posted ContentDOI
Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China
Penghui Yang,Yibo Ding,Zhe Xu,Rui Pu,Ping Li,Jin Yan,Jiluo Liu,Fanping Meng,Lei Huang,Lei Shi,Tian-Jun Jiang,Enqiang Qin,Min Zhao,Dawei Zhang,Peng Zhao,Ling-Xiang Yu,Zhaohai Wang,Zhi-Xian Hong,Zhao-Hui Xiao,Qing Xi,Dexi Zhao,Peng Yu,Caizhong Zhu,Zhu Chen,Shaogeng Zhang,Junsheng Ji,Guangwen Cao,Fu-Sheng Wang +27 more
TL;DR: The epidemiological features are important for COVID-19 prophylaxis, including circulating interleukin-6 and lactateare independent prognostic factors, and CD8+ T cell exhaustion might be critical in the development of CO VID-19.